Finding the Latent Treponema Pallidum

Study Overview
=================
Brief Summary
-----------------
Some syphilitic patients remain in a serologically positive state after the recommended therapy. Whether a serofast state could represent a persistent low-level infection by Treponema pallidum is still unknown. The possibility that persistent nontreponemal antibodies after treatment represent persistence of Treponema pallidum was raised by some investigators. The investigators use the Next-Generation Sequencing to test blood plasma, srum, cerebrospinal fluid, aqueous humor, lymph nodes, skin lesion, saliva, semen,milk of serofast patient and other positive and negative controls.

Detailed Description
-----------------
Some syphilitic patients remain in a serologically positive state after the recommended therapy. Whether a serofast state could represent a persistent low-level infection by Treponema pallidum is still unknown. The possibility that persistent nontreponemal antibodies after treatment represent persistence of Treponema pallidum was raised by some investigators. The investigators use the Next-Generation Sequencing to test blood plasma, serum, cerebrospinal fluid, aqueous humor, lymph nodes, skin lesion, saliva, semen,milk of serofast patient and other positive and negative controls.

Official Title
-----------------
Finding the Latent Treponema Pallidum of Syphilis With Serofast Status

Conditions
-----------------
Syphilis

Intervention / Treatment
-----------------
* Diagnostic Test: RPR Titer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All clinical diagnosis of syphilis cases Exclusion Criteria: Auto-immune disease (such as SLE) Lyme disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Serofast status<br>The syphilitic patients who remain in a serologically positive state after therapy | Diagnostic Test: RPR Titer<br>* RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing<br>|
| Untreated<br>untreated syphilis cases | Diagnostic Test: RPR Titer<br>* RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing<br>|
| Serological cure<br>In the early syphilis patients, at 6 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer. In the late syphilis patients, at 12 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer. | Diagnostic Test: RPR Titer<br>* RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the reads of treponema pallidum | Using the Next-Generation Sequencing to test specific genome of treponema pallidum for syphilis | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
syphilis, serofast